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Introduction: The association between endometriosis and breast cancer is unclear. We 
assessed the risk of breast cancer in women with surgically verified endometriosis, with 
special focus on the age at cancer diagnosis, time from endometriosis diagnosis and breast 
cancer histology. Material and Methods: All women with first endometriosis associated 
diagnoses occurring concomitantly with relevant surgical codes during 1987-2012 were 
retrieved from the Finnish Hospital Discharge Register in Finland. Breast cancers diagnosed 
after the endometriosis diagnosis were identified from the Finnish Cancer Registry. The 
Finnish female population served as the reference. The endometriosis cohort consisted of 
49 933 women (23 210 cases of ovarian, 20 187 peritoneal and 2372 deep infiltrating 
endometriosis). The outcome measure was the standardized incidence ratio (SIR) with 95% 
confidence interval (95%CI) of breast cancer calculated for the whole cohort and for the 
subtypes of endometriosis, stratified by the age at breast cancer diagnosis, histology, and time 
from endometriosis diagnosis. Results: The overall risk of breast cancer (1555 cases) was 
similar to the reference population (SIR 0.99; 95%CI 0.94 to 1.03), did not differ in types of 
endometriosis, and was similar for ductal and lobular breast cancer.  However, the SIR of 
breast cancer was increased in the age group of 20-29 years (4.44; 95%CI 2.22 to 7.94), and 
in the age group of 30-39 years (1.28; 1.03 to 1.57). The risk of in situ breast cancer (170 
cases) was increased in the entire endometriosis cohort (1.25; 1.07-1.44). Conclusions: The 
overall risk of breast cancer in women with surgically verified endometriosis was similar to 
that of general population. However, the risk of breast cancer at young age was increased. 
Young women with surgically verified endometriosis represent highly symptomatic patients 
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Endometriosis is a chronic inflammatory disease of the female pelvis affecting 6-10% of 
fertile-age women, resulting in increased morbidity including pelvic pain and subfertility.
1
 
The risk factors relate to increased exposure to menstruation, such as early menarche, short 
menstrual cycle length, and longer menstrual duration, as well as reduced parity.
1 
The 
etiology is uncertain, but it includes genetic, environmental and immunological 
abnormalities.
2 
A key feature of ectopic endometriotic implants is their capacity for 
autonomic estrogen production.
3
 In clinical practice, endometriosis is divided into three 
different subgroups, i.e., ovarian, peritoneal and deep infiltrating endometriosis. The 




Breast cancer is the most common cancer and cause of cancer death in women worldwide.
5
 
General risk factors include genetic factors, reproductive, hormonal and life-style related 
factors such as nulliparity, early menarche or late menopause, current or recent use of oral 
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Previous studies assessing the relationship between endometriosis and breast cancer have 
reported conflicting results. Some recent large studies have suggested that the risk of breast 
cancer among endometriosis patients is increased 
7-9
, whereas several other studies reported 
no such risk
10-15





We have previously assessed the risk of gynecological and non-gynecological cancers 
according to the type of endometriosis.
17 18 
We found that the overall risk of breast cancer in 
women with surgically verified endometriosis was similar to that of the Finnish female 
population.
17
 Moreover, the risk did not differ according to the type of endometriosis. 
However, as breast cancer is the most common cancer among fertile-aged women and a 
concern to all women we further explored the risk of breast cancer according to age at breast 
cancer diagnosis, time from endometriosis diagnosis as well as breast cancer histology (i.e. 
ductal and lobular) and separately for breast carcinoma in situ. 
 
MATERIAL AND METHODS 
 
In this historic register-based cohort study all first diagnoses of endometriosis, either main or 
subsidiary, were identified from the Finnish Hospital Discharge Registry when existing 
concomitantly with a relevant procedural code for the first time from 1987 to 2012. The 
Finnish Hospital Discharge Registry has national coverage and includes personal identity 
codes, codes for diseases according to the International Classification of Diseases (ICD), 
procedure codes according to the Nordic Medico-Statistical Committee Classification of 
Surgical Procedures (NCSP) and dates for each hospital visit and surgery. The ICD codes are 
set by the physician in charge of the patient and chosen for each hospital visit based on their 
clinical relevance. The registry includes records both from public and private hospitals, and 
also outpatient surgeries from 1994 onwards. The index day was the discharge day of the first 





Information on the incident histologically verified carcinoma in situ and breast cancers in the 
endometriosis cohort were assessed by linkage to the Finnish Cancer Registry using the 
personal identity codes, which are available for all permanent residents in Finland. This 
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topography and morphology of all malignancies diagnosed in Finland since 1953 allowing 
also analyses by histology and stage of the disease.
20 
The breast tumor hormone receptor 
status is not registered. The follow-up started on the index day and ended either on the day of 
emigration, death, or December 31
st
, 2014 whichever came first. The data on emigrations and 
deaths were retrieved from the Finnish Population Register Centre.  
 
The endometriosis cohort consisted of 49 933 women who were assigned to sub-cohorts of 
ovarian (n=23 210), peritoneal (n=20 187), deep infiltrating (n=2372), mixed (n=1120) and 
“other/unknown” endometriosis (n=3044) according to the site of endometriosis using the 
diagnostic codes from ICD versions 9 and 10 assigned at the index procedure (Supporting 
Information Table S1). First, the categories of ovarian and deep infiltrating endometriosis 
were retrieved. The combination of both ovarian and deep infiltrating endometriosis formed 
the sub-cohort of mixed endometriosis. Second, the category of peritoneal endometriosis was 
selected. Third, those not stratified into previous four categories formed the sub-cohort of 
“other/unknown” endometriosis. The categories of ovarian, deep infiltrating, and mixed 
endometriosis could also include additional diagnoses of peritoneal endometriosis and/or 
other/unknown endometriosis. The sub-cohort of peritoneal endometriosis could also include 
additional diagnoses of other/unknown endometriosis but not ovarian, deep infiltrating, nor 
mixed endometriosis.
19
 Cases with adenomyosis as the only diagnosis were excluded, as 
histological data to confirm the diagnoses were not available. We focused on the three main 
sub-cohorts: ovarian, peritoneal and deep infiltrating endometriosis. 
 
Statistical analyses 
Women were divided to age groups by ten years intervals (20-29, 30-39, 40-49, 50-59, 60-69, 
≥70). Person-years of follow-up were calculated by five-year age categories and calendar 
periods, and by time since the index day (<0.5, 0.5-4.9, 5-9.9, ≥10 years). The expected 
number was defined by multiplying the accumulated person-years of follow-up in each 
stratum by breast cancer incidence rate in the corresponding Finnish female population. The 
standardized incidence ratio (SIR) was calculated as the ratio between the observed and the 
expected number of cancers. The 95% confidence intervals (95%CI) for the SIR were defined 
on the assumption that the number of observed cases followed a Poisson distribution. In the 
stratified analyses the same calculations were performed according to the histology 
(ductal/lobular/in situ carcinoma) and stage of the breast cancer (localized/non-localized) and 
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There were altogether 838 685 person-years of follow-up during 1987-2014 with mean 
follow-up time was 16.8 years.  Six percent of the person-years accumulated in age 
categories under 30 years, 60% under 50 years and 14% in ages over 60 years (Table 1). The 
sub-cohorts of ovarian and peritoneal endometriosis represented 89% of all person-years. The 
median age on the index day was 36.4 years. 
 
The overall incidence of breast cancer was similar to that in the Finnish female population in 
the entire endometriosis cohort (1555 observed cases, SIR 0.99; 95%CI 0.94 to 1.03) and in 
all sub-cohorts of endometriosis (Table 2, Supporting Information Table S2). An increased 
risk of breast cancer was seen in the 20 to 29 -year-olds (SIR 4.44; 95%CI 2.22 to 7.94, 11 
cases), and in the 30-39 -year-olds (1.28; 1.03 to 1.57, 90 cases). Moreover, a slightly 
decreased risk of breast cancer was observed among the 50 to 59 -year-old women (0.92; 
0.85 to 0.99) (Table 2).  
 
Eleven women with endometriosis had the diagnosis of breast cancer at the age of less than 
30 years (Table 3). The SIR of localized breast cancer in the 20-29 -year-olds was 5.80 
(95%CI 2.13 to 12.6, 6 cases) while that of non-localized disease was 3.15 (0.86 to 8.07, 4 
cases). The corresponding numbers among the 30-39 -year-olds were 1.50 (1.09 to 2.02, 43 
cases) and 1.12 (0.81 to 1.51, 42 cases).  
 
In the stratified analyses the SIR of the breast cancer diagnosis increased 0.5-4.9 years after 
the endometriosis diagnosis in the whole cohort (1.15; 1.01 to 1.29), and especially in the 
sub-cohort of peritoneal endometriosis (1.30; 1.06 to 1.56). (Table 2) 
 
The SIR for ductal histology was 0.97 (0.91 to 1.02) and for lobular histology 0.99 (0.87 to 
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1.91 to 7.92, 9 cases). The overall incidence of in situ carcinoma of the breast (n=170) was 
increased in women with endometriosis (1.25; 1.07 to 1.44). The risk of in situ carcinoma 




We observed that women with surgically verified endometriosis do not have an overall 
increased risk of breast cancer. The risk did not differ according to the type of endometriosis 
either. The distribution of ductal and lobular histology of breast cancer did not differ from the 
reference population. However, we found an increased incidence of breast cancer among the 
20-39 -year-olds. The incidence of carcinoma in situ of the breast was increased.  
 
The non-elevated overall incidence of breast cancer among women with endometriosis has 
been shown in several previous studies with different study designs and ascertainments of the 
diagnosis of endometriosis.
10-14
 A large British cohort study published in 2018 found no 
association between breast cancer and endometriosis among women receiving infertility 
treatment with assisted reproductive technologies.
15
 In contrast, an increased incidence of 




The differences in the overall incidence of breast cancer between different subtypes of 
endometriosis were small in our study. In two previous Nordic studies, the risk of breast 
cancer has also been assessed in relation to the site of endometriosis (ovarian, pelvic, uterine 
and other endometriosis).
7 11 
The Swedish study found an increased risk of breast cancer with 
pelvic (SIR 1.8; 95%CI 1.2 to 2.6) and uterine (SIR 1.4; 95%CI 1.1 to 1.7) but not with 
ovarian endometriosis.
7
 The Danish study did not find altered risks of breast cancer in any of 
the different locations of endometriosis.
11
 
On the contrary to our study a recent register-based study from Denmark found an increased 
risk of breast cancer in women with first diagnosis of endometriosis at ≥50 years of age (SIR 
1.27; 1.12 to 1.42).
13
 Moreover, a previous partially overlapping Danish register-based study 
reported that the risk of breast cancer was decreased if the endometriosis diagnosis had been 
made at <40 years of age but increased along with increasing age at the first endometriosis 
diagnosis.
11
 A Swedish register-based study found an increased risk of breast cancer (SIR 
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age.
10
 In contrast, a prospective study from the USA reported that the risk of breast cancer 
was not increased in premenopausal or postmenopausal women with endometriosis.
14 
 
Early onset breast cancer is rare, and therefore, the absolute excess risk based on our study is 
small: in the age group of 20 to 29 -year-olds, the relative risk of 4.4 would translate into 
eight breast extra cancers among 10 000 women with endometriosis followed-up for five 
years. In the age group of 30 to 39 -year-olds, the corresponding number would be five.  
The reasons for the increased risk of breast cancer among young women with surgically 
diagnosed endometriosis is uncertain. Similar risk factors for both endometriosis and young-
age breast cancer might in part explain our finding. The known risk factors of early onset 
breast cancer, such as family history and known genetic predisposition, explain only 
approximately 10% of young-age breast cancer cases.
21
 However, we speculate that genetic 
factors predisposing to breast cancer might be more frequent among women with 
endometriosis at early age. Other possible risk factors for breast cancer in young women 
include low body mass index and use of oral contraceptives.
21
 The women operated for 
endometriosis at a young age are also likely to be highly symptomatic and therapies used in 
addition to surgery for symptom control, such as hormonal treatments and analgesics, might 
differently affect the risk of breast cancer in these women compared to older women with less 
symptoms.
 22 23
  Recent meta-analyses indicated a slightly increased risk of breast cancer 
associated with current or recent use of hormonal contraceptives (risk ratio for current users 
1.3; 95%CI 1.1 to 1.5 and for ever-users 1.1; 95%CI 1.0 to 1.2) 
24 25 
The use of progestin-only 
contraceptives has also been linked with breast cancer.
26 27
 In Finland, oral contraceptives and 
progestins are widely used in the treatment of endometriosis. In our study, data on hormonal 
therapies were not available, and therefore, the effect of hormonal therapies could not be 
estimated. According to the abovementioned facts, we speculate that in our study the SIRs 
would be lower if we could have adjusted for hormonal therapies.  
Breast cancer occurring at a young age is known to be aggressive and commonly diagnosed 
at a non-localized stage.
21 
The proportion of non-localized stage young-age breast cancer in 
our data was however lower than in the breast cancer patients of similar age in the reference 
population, as indicated by the higher SIR for a localized than for a non-localized stage of the 
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more often and therefore breast cancers of young women with endometriosis are diagnosed 
earlier than in the reference population.  
The risk of breast cancer was slightly decreased among 50-59 -year old women with 
endometriosis (0.9-fold, 95%CI 0.9 to 1.0). On the other hand, the SIR of in situ cancers was 
increased in the age group of 40 to 59 -year-olds. Endometriosis patients at 40 years of age or 
older might receive breast imaging examinations more frequently than the average female 
population. This may lead to increased detection of in situ cancers and their timely treatment, 
resulting in decreased risk of breast cancer.  
A strength of our study is in the high-accuracy of the registers.
 20 28  
The cohort data from the 
Finnish Hospital Discharge Registry, cancer data from the Finnish Cancer Registry, and the 
data on deaths and emigrations from the Finnish Population Register Centre were reliably 
linked using the unique personal identity codes available in all registries. Additional strengths 
of the study are the 27 years long study period with almost 840 000 person-years and more 
than 1500 breast cancer cases. The large cohort size and the surgically verified diagnoses of 
endometriosis gave us the possibility to assess the breast cancer risks for various subtypes of 
endometriosis. Still, the sub-cohort of deep infiltrating endometriosis is too small for reliable 
conclusions; deep infiltrating endometriosis is rare, and the definition of the disease entity 
was established only in the 1990s.
  
Furthermore, our follow-up does not properly extend into 
the oldest age groups – there were only 48 breast cancer cases in age groups of 70 years or 
more – and therefore our results on breast cancer risk in old age remain uninformative.  
A limitation of this study is the lack of possibility to adjust the results for important potential 
confounding factors that might bias the SIRs of our study. The decreased parity or late onset 
of first pregnancy among women with endometriosis could increase the risk of breast cancer.
 
The body mass index is decreased in women with endometriosis, which might lead to an 
increased incidence of breast cancer in premenopausal and a decreased incidence of breast 
cancer in postmenopausal women.
29 30
 Furthermore, data on hormonal therapies, a cause of 
possible bias in the study, were unavailable. We speculate that hormone replacement therapy 
is likely to be used less often due to the risk of endometriosis recurrence and therefore 










This article is protected by copyright. All rights reserved. 
CONCLUSION 
 
The overall incidence of breast cancer was not increased in women with surgically verified 
endometriosis nor was the risk increased in any of the specific types of endometriosis. The 
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Supporting Information legends 
 
Table S1. Types of endometriosis and the possible additional diagnosis of endometriosis. 
 
Table S2. Breast cancers and carcinoma in situ lesions of the breast among women with 
endometriosis, by the type of endometriosis and by dynamic age at follow-up: observed 
number of cases (O), standardized incidence ratios (SIR) and 95% confidence intervals (CI).  
 
Legends to the tables  
 
Table 1. Number of women with surgically verified endometriosis by age in the beginning of 
the follow-up, and numbers of person-years by dynamic age at follow-up. 
 
Table 2. Breast cancers and carcinoma in situ lesions of the breast among women with 
endometriosis, by time since endometriosis diagnosis and by dynamic age at follow-up: 
observed number of cases (O), standardized incidence ratios (SIR) and 95% confidence 
interval (CI). 
 
Table 3. Details of women with endometriosis and subsequent breast cancer diagnosed under 
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Table 1. Number of women with surgically verified endometriosis by age in the beginning of 









Person-years, by years since endometriosis diagnosis  




     
10-19 525  228 440 8 0 676  
20-29 12 685  6135 35 577 9048 452 51 212  
30-39 18 027  9027 79 485 66 145 31 458 186 115  
40-49 15 286  7766 75 103 77 531 102 746 263 145  
50-59 2985  1580 25 218 53 628 140 137 220 562  
60-69  339  178 2392 7125 90 754 100 449 
≥70 86 45 564 1067 14 850 16 526 











Table 2. Breast cancers and carcinoma in situ lesions of the breast among women with endometriosis, by time since endometriosis diagnosis and 
by dynamic age at follow-up: observed number of cases (O), standardized incidence ratios (SIR) and 95% confidence interval (CI). 
Dynamic age at  
follow-up 
(years) 
Time since endometriosis diagnosis 






≥ 10 years 
 
Total 
O SIR 95%CI O SIR 95%CI O SIR 95%CI O SIR 95%CI O SIR 95%CI 
Breast cancer 
20-29
 0 0.00 0.00-14.5 7 4.18 1.68-8.60 4 7.69 2.10-19.7 0 0.00 0.00-130 11 4.44 2.22-7.94 
30-39
 2  0.64 0.08-2.30 37 1.33 0.93-1.82 36 1.43 1.00-1.97 15 1.08 0.61-1.78 90 1.28 1.03-1.57 
40-49 11 1.00 0.50-1.79 114 1.01 0.83-1.20 112 0.91 0.75-1.08 194 1.16 1.01-1.33 431 1.04 0.95-1.14 
50-59
 4 0.98 0.27-2.51 80 1.19 0.95-1.48 116 0.77 0.64-0.92 389 0.93 0.84-1.02 589 0.92 0.85-0.99 
60-69 0 0.00 0.00-7.07 13 1.74 0.92-2.96 23 0.94 0.60-1.41 350 0.97 0.87-1.07 386 0.98 0.89-1.08 
≥70 0 0.00 0.00-28.4 0 0.00 0.00-2.22 2 0.61 0.10-2.02 46 0.89 0.65-1.19 48 0.86 0.63-1.14 
Total 17 0.89 0.52-1.42 251 1.15 1.01-1.29 293 0.90 0.80-1.00 994 0.98 0.92-1.04 1555 0.99 0.94-1.03 
Carcinoma in situ 
20-29 0 0.00 0.00-331 0 0.00 0.00-52.8 0 0.00 0.00-180 0 0.00 0.00-4155 0 0.00 0.00-36.0 
30-39 0 0.00 0.00-29.5 3 2.53 0.52-7.40 0 0.00 0.00-3.19 0 0.00 0.00-5.22 3 0.95 0.20-2.76 
40-49 1 1.66 0.04-9.26 4 0.59 0.16-1.50  13 1.60 0.85-2.73 22 1.67 1.05-2.52 40 1.39 1.00-1.89 
50-59 0 0.00 0.00-11.1 9 1.55 0.71-2.94 23 1.64 1.04-2.46 53 1.23 0.92-1.61 85 1.35 1.08-1.66 
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No cases of breast cancer or carcinoma in situ of the breast were found in the age group of 10-19 years (observed 0, expected <0.005).   
 
60-69 0 0.00 0.00-105 0 0.00 0.00-6.69 1 0.49 0.01-2.73 37 1.06 0.75-1.46 38 1.01 0.72-1.39 
≥70 0 0.00 0.00-787 1 14.3 0.36-79.6 0 0.00 0.00-24.6 3 0.96 0.20-2.81 4 1.19 0.33-3.06 
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Table 3. Details of women with endometriosis and subsequent breast cancer diagnosed under 
30 years of age. 
 






  Grade Type TNM 










Ovarian 2.4 26.7 II ductal T1N0M0 Yes (12.0) 24.9 
Ovarian 5.6 28.6 II ductal T1N1MX Yes (2.2) 4.3 
Ovarian 5.7 28.9 III ductal T1N0MX No 4.8 
Peritoneal 0.7 28.2 III ductal T1N1M0 No 1.9 
Peritoneal 1.8 26.8 N/A N/A N/A N/A 11.3 
Peritoneal 4.8 29.0 III ductal T1N1M0 No 8.4 
Deep 3.4 27.9 III ductal T1N0M0 No 12.7 
Deep 7.4 29.0 III ductal T1N0M0 No 2.9 
Other 1.1 28.1 N/A ductal T1N0M0 Yes (2.7)
4
  4.9 
Other 1.5 27.6 III ductal T3N1M0 No 15.2 
Other 5.9 28.7 II cribriform T1N0MX No 1.5 
1
Years between endometriosis diagnosis and breast cancer diagnosis.  
2
Age at breast cancer diagnosis (years).  
3
 Recurrence (yes/no) during the follow-up and the time of possible recurrence.  
4 
This person also died due to breast cancer 4.9 year after breast cancer diagnosis. 
5 
Follow-up from breast cancer diagnosis until death or 31 Dec 2014 (years).
 
N/A – Not available 
 
 
 
 
